skip to the content

Avastin controls tumour growth

The Avastin MoA has multiple clinical implications

  • Angiogenesis is one of the key acquired characteristics or ‘hallmarks’ essential for the growth and development of all tumour types1
    • the anti-angiogenic agent Avastin has demonstrated clinical efficacy in a range of different tumour types, regardless of tumour or patient characteristics2–5
    • clinical trials have reported that Avastin can be combined safely and effectively with both chemotherapy and immunotherapy.2–5
 

Efficacy of Avastin

 
  • The continuous expression of VEGF throughout the tumour life cycle validates the use of Avastin up to tumour progression
    • this is supported by data from Avastin clinical trials.6–9
 

Optimal duration of Avastin therapy

 
  • Precise VEGF inhibition by Avastin limits the development of additional toxicity such as the AEs produced by ‘off-target’ effects of multitargeted TKIs.10–11
 

Precise VEGF inhibition limits toxicity  

 

References

  1. Hanahan D, Weinberg RA. Cell 2000;100:57–70.
  2. Hurwitz H, Fehrenbacher L, Novotny W, et al. N Engl J Med 2004;350:2335–42.
  3. Sandler A, Gray R, Perry MC, et al. N Engl J Med 2006;355:2542–50.
  4. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. J Clin Oncol 2009;27:4966–72.
  5. Escudier B, Pluzanska A, Koralewski P, et al. Lancet 2007;370:2103–11.
  6. Saltz L, Clarke S, Díaz-Rubio E, et al. J Clin Oncol 2008;26:2013–9.
  7. Saltz L, Clarke S, Díaz-Rubio E, et al. J Clin Oncol 2007;25(June 20 Suppl.):170s (Abstract 4028 and associated poster and oral presentations).
  8. Grothey A, Sugrue MM, Purdie DM, et al. J Clin Oncol 2008;26:5326–34.
  9. Grothey A, Sugrue M, Hedrick E, et al. J Clin Oncol 2007;25(June 20 suppl):172s (Abstract 4036 and associated poster presentation).
  10. Kamba T, McDonald DM. Br J Cancer 2007;96:1788–95.
  11. Verheul HMW, Pinedo HM. Nat Rev Cancer 2007;7:475–85.

Avastin TV

Watch Dr Fairooz Kabbinavar as he presented “Controlling angiogenesis to control tumour growth” at the Anti-angiogenesis Clinical Experience Exchange Meeting held in Madrid, Spain in April 2009.